Raltegravir - Merck & Co

Drug Profile

Raltegravir - Merck & Co

Alternative Names: Isentress; ISENTRESS HD; L 900612; MK-0518; RAL

Latest Information Update: 11 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; National Institute of Allergy and Infectious Diseases; The French National Agency for Research on AIDS and Viral Hepatitis
  • Class Antiretrovirals; Naphthyridines; Organic chemicals; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 07 Sep 2018 Intellectual Property High Court of Japan dismisses Shionogi’s lawsuit filed against MSD in Japan
  • 24 Jun 2018 Biomarkers information updated
  • 15 May 2018 Registered for HIV-1 infections in Japan (PO, 1200mg: 2 600mg tablets)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top